Madrigal Pharmaceuticals (MDGL)

• Market cap: $9.88B
• 1 day: -1.13%
• 5 days: -3.76%
• 1 month: -12.85%
• 3 months: -26.52%
• 6 months: 5.53%
• Year to date: -26.75%
• 1 year: 40.56%
• 5 years: 253.49%
• 10 years: 5,593.85%
• Sector: Healthcare
• Industry: Biotechnology

About: Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.

Employees: 528